Skip to main content
SpringerLink
Log in

Protease inhibitor monotherapy cost effective for HIV

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Protease Inhibitor monotherapy Versus Ongoing Triple therapy

  2. 2012 British pounds

  3. ongoing triple therapy

Reference

  • Oddershede L, et al. Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT Trial. PharmacoEconomics : 10 Mar 2016. Available from: URL: http://doi.org/10.1007/s40273-016-0396-x

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Protease inhibitor monotherapy cost effective for HIV. PharmacoEcon Outcomes News 749, 28 (2016). https://doi.org/10.1007/s40274-016-2915-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-2915-6

Search

Navigation